273 related articles for article (PubMed ID: 30382189)
21. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
[TBL] [Abstract][Full Text] [Related]
22. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer.
Mazumdar T; DeVecchio J; Agyeman A; Shi T; Houghton JA
Oncotarget; 2011 Aug; 2(8):638-45. PubMed ID: 21860067
[TBL] [Abstract][Full Text] [Related]
23. Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer.
Kowolik CM; Lin M; Xie J; Overman LE; Horne DA
J Exp Clin Cancer Res; 2019 Oct; 38(1):431. PubMed ID: 31661013
[TBL] [Abstract][Full Text] [Related]
24. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
[TBL] [Abstract][Full Text] [Related]
25. GANT-61 and GDC-0449 induce apoptosis of prostate cancer stem cells through a GLI-dependent mechanism.
Tong W; Qiu L; Qi M; Liu J; Hu K; Lin W; Huang Y; Fu J
J Cell Biochem; 2018 Apr; 119(4):3641-3652. PubMed ID: 29231999
[TBL] [Abstract][Full Text] [Related]
26. A Critical Function for the Transcription Factors GLI1 and GLI2 in the Proliferation and Survival of Human Mast Cells.
Falduto GH; Pfeiffer A; Zhang Q; Yin Y; Metcalfe DD; Olivera A
Front Immunol; 2022; 13():841045. PubMed ID: 35251038
[TBL] [Abstract][Full Text] [Related]
27. Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.
Ooki A; Dinalankara W; Marchionni L; Tsay JJ; Goparaju C; Maleki Z; Rom WN; Pass HI; Hoque MO
Oncogene; 2018 Nov; 37(45):5967-5981. PubMed ID: 29980786
[TBL] [Abstract][Full Text] [Related]
28. Cathepsin B and uPAR regulate self-renewal of glioma-initiating cells through GLI-regulated Sox2 and Bmi1 expression.
Gopinath S; Malla R; Alapati K; Gorantla B; Gujrati M; Dinh DH; Rao JS
Carcinogenesis; 2013 Mar; 34(3):550-9. PubMed ID: 23222817
[TBL] [Abstract][Full Text] [Related]
29. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
30. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
[TBL] [Abstract][Full Text] [Related]
31. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
[TBL] [Abstract][Full Text] [Related]
32. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
33. DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Gruber W; Hutzinger M; Elmer DP; Parigger T; Sternberg C; Cegielkowski L; Zaja M; Leban J; Michel S; Hamm S; Vitt D; Aberger F
Oncotarget; 2016 Feb; 7(6):7134-48. PubMed ID: 26784250
[TBL] [Abstract][Full Text] [Related]
34. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft.
Fu J; Rodova M; Roy SK; Sharma J; Singh KP; Srivastava RK; Shankar S
Cancer Lett; 2013 Mar; 330(1):22-32. PubMed ID: 23200667
[TBL] [Abstract][Full Text] [Related]
35. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Sagar S; Leiphrakpam PD; Thomas D; McAndrews KL; Caffrey TC; Swanson BJ; Clausen H; Wandall HH; Hollingsworth MA; Radhakrishnan P
Cancer Lett; 2021 Apr; 503():91-102. PubMed ID: 33485947
[TBL] [Abstract][Full Text] [Related]
36. Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling Pathway.
Zhuang L; Yao Y; Peng L; Cui F; Chen C; Zhang Y; Sun L; Yu Q; Lin K
Dig Dis Sci; 2022 Aug; 67(8):3773-3782. PubMed ID: 34623580
[TBL] [Abstract][Full Text] [Related]
37. SOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells.
Santini R; Pietrobono S; Pandolfi S; Montagnani V; D'Amico M; Penachioni JY; Vinci MC; Borgognoni L; Stecca B
Oncogene; 2014 Sep; 33(38):4697-708. PubMed ID: 24681955
[TBL] [Abstract][Full Text] [Related]
38. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
39. Abnormal activity of transcription factors gli in high-grade gliomas.
Volnitskiy A; Shtam T; Burdakov V; Kovalev R; Konev A; Filatov M
PLoS One; 2019; 14(2):e0211980. PubMed ID: 30730955
[TBL] [Abstract][Full Text] [Related]
40. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Asuthkar S; Stepanova V; Lebedeva T; Holterman AL; Estes N; Cines DB; Rao JS; Gondi CS
Mol Biol Cell; 2013 Sep; 24(17):2620-32. PubMed ID: 23864708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]